Opinion

Video

Durability of Effect and Advice to Improve Quality of Life in Atopic Dermatitis

Shawn Kwatra, MD, discusses the durability of treatments for atopic dermatitis and provides advice for clinicians on improving patients’ quality of life.

Video content above is prompted by the following questions:

  • How durable is the impact of AD treatments on patients’ QoL?
    • What advice can you share with clinicians to improve the quality of life of patients with AD?
Related Videos
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
© 2024 MJH Life Sciences

All rights reserved.